Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval

shutterstock_1436984567
Ocrevus boasts a superior pharmacological profile in multiple sclerosis (MS) market due to its high efficacy, good tolerability, and convenient six-month dosing regimen via intravenous (IV) infusion. Credit: Lightspring / Shutterstock.